Yoshie Umemura, MD

Clinical Assistant Professor


Dr. Umemura is a clinical assistant professor in the Department of Neurology in the University of Michigan Medical School. She obtained Bachelor of Science degree from University of California, Riverside, and studied medicine at St. George's University. Dr. Umemura completed Neurology residency at Dartmouth-Hitchcock Medical Center before completing Neuro-Oncology fellowship at Memorial Sloan Kettering Cancer Center in New York City. Dr. Umemura is board certified in Neurology and Neuro-Oncology, and sees patients in the Neuro-Oncology Clinic at the Rogel Cancer Center. 

Areas of Interest

Dr. Umemura is the Principal Investigator of the following studies:

A Phase III/III Randomized Trial of Veliparib or Placebo in Combination with Adjuvant Temozolomide in Newly Diagnosed Glioblastoma with MGMT Promotor Hypermethylation 

Patient and Clinician Based Perspectives of Lumbar Puncture: A Survey Based Study


Dr. Umemura is a Co-Investigator of the following studies:

A Non-randomized, Open-label Dose-finding Trial of Combined Cytotoxic and Immune-stimulatory Strategy for the Treatment of Resectable Primary Malignant Glioma

Phase II Study of High Dose Radiotherapy and Concurrent Temozolomide Using Biologically-Based Target Volume Definition in Patients with Newly Diagnosed Glioblastoma

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

A Prospective Study Using Genomic, Histologic and Radiomic Analysis to Evaluate Regional Tumor Heterogeneity in Patients Undergoing Surgery for Newly Diagnosed Glioblastoma 

Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT Or Proton Beam Therapy Versus Conventional Photon Irradiation with Concomitant and Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma

Phase III Intergroup Study of Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma

Phase III Trial of Observation Versus Irradiation for A Gross Totally Resected Grade II Meningioma

Maintenance Obinutuzumab for Primary Central Nervous System Lymphoma Complete Responders

A Phase 2 Study of Panobinostat in Combination with Everolimus for Children and Young Adults with Gliomas Harboring H3.3 or H3.1 K27M Mutation

Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas

Pilot Study of Cerebrospinal Fluid Circulating Biomarkers in Solid Tumor Patients

RTOG 1119 Phase II Randomized Study of Whole Brain Radiotherapy/Stereotactic Radiosurgery in Combination with Concurrent Lapatinib in Patients with Brain Metastasis from HER2-Positive Breast Cancer- A Collaborative Study of NRG Oncology and KROG

Randomized Phase II Study: Corticosteroids + Bevacizumab VS. Corticosteroids + Placebo (BeSt) for Radionecrosis After Radiosurgery for Brain Metastases

Phase 1 and Pharmacology Study of Oral 5-iodo-2-pyrimidinone-2-deoxyribose (IPdR) as a Prodrug for IUdR-Mediated Tumor Radiosenitization in Brain Metastases

Clinical Interests

  • Brain Tumors  


Medical School or Training

  • St. George's University School of Medicine, 2011


  • Dartmouth-Hitchcock Medical Center, Neurology, NH, 2015
  • Brookdale University Hospital and Medical Center, Internal Medicine, NY, 2012


  • Neuro-Oncology, Memorial Sloan Kettering Cancer Center, 2017

Board Certification

  • Neurology

Web Sites